title: Off-label use of drugs and devices in the neuroendovascular suite.
abstract: The off-label use of drugs and devices in neuroendovascular procedures is common. Neurointerventionalists should be well aware of the level of evidence available in support of the off-label use of drugs and devices in their practice and some of the potential adverse events associated with them. These uses are categorized as I or II if they have been evaluated as primary or ancillary interventions in prospective trials/registries of neuroendovascular procedures and III if they were evaluated in case series. Category IV use is based on evaluation as primary or ancillary interventions in prospective trials/registries of non-neuroendovascular procedures. Physicians are allowed to use off-label drugs and procedures if there is strong evidence that they are beneficial for the patient. The neurointerventional professional societies agree that off-label use of drugs and devices is an important part of the specialty, but practicing providers should base their decisions on sound evidence when using such drugs and devices.
authors.affiliation: Zeenat Qureshi Stroke Research Center.
authors.forename: M M
authors.initials: MM
authors.lastname: Abdihalim
authors.forename: A E
authors.initials: AE
authors.lastname: Hassan
authors.forename: A I
authors.initials: AI
authors.lastname: Qureshi
mesh_terms: D001807:Blood Vessel Prosthesis; D002548:Cerebral Revascularization / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods*; D002561:Cerebrovascular Disorders / Q000628:therapy*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D056687:Off-Label Use; D015607:Stents
chemical_list: D005343:Fibrinolytic Agents